AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
NCT07158840
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
AK112
Sponsor
Akeso